Effect of ASP6432, a Novel Type 1 Lysophosphatidic Acid Receptor Antagonist, on Urethral Function and Prostate Cell Proliferation

Kazuyuki Sakamoto, Yukiko Noguchi, Koji Ueshima, Hisashi Yamakuni, Akiyoshi Ohtake, Shuichi Sato, Kenichiro Ishizu, Naomi Hosogai, Eiji Kawaminami, Masahiro Takeda, and Noriyuki Masuda

Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Ibaraki, Japan (K.S., Y.N., K.U., A.O., S.S., K.I., N.H., E.K., M.T., N.M.), Astellas Research Technologies Co., Ltd., Tsukuba, Ibaraki, Japan (H.Y.) and School of Integrative and Global Majors, University of Tsukuba, Tsukuba, Ibaraki, Japan (K.S.)

Received January 22, 2018; accepted May 30, 2018

ABSTRACT

Current pharmacotherapies for lower urinary tract symptoms associated with benign prostate hyperplasia (LUTS/BPH) are in need of improvement. Lysophosphatidic acid (LPA) is a phospholipid with various biologic functions. However, its exact role in the lower urinary tract and its target receptor subtype have not been fully elucidated. We investigated the role of LPA and the type 1 LPA receptor (LPA1) in urethral/prostatic contractile function and prostate cell proliferation by pharmacologically characterizing ASP6432 (potassium 1-((3,5-dimethoxy-4-methyl-N-(3-phenylpropyl)benzamido)methyl)-1,3-thiazole-4-carbonyl)-3-ethyl-2,2-dioxo-2H-diazathian-1-ide), a novel LPA1 antagonist. ASP6432 exhibited potent and selective antagonistic activity against LPA1 in cells expressing LPA receptor subtypes. In isolated rat tissue strips and anesthetized rats, ASP6432 concentration–dose-dependently inhibited LPA-induced urethra and prostate contractions. In addition, in anesthetized rats, ASP6432 maximally decreased the urethral perfusion pressure (UPP) in the absence of exogenous LPA stimulation by 43% from baseline, whereas tamsulosin, an α1-adrenoceptor antagonist, reduced UPP by 22%. Further, in human prostate stromal cells, ASP6432 significantly and concentration-dependently suppressed LPA-induced bromodeoxyuridine incorporation. These results demonstrate a pivotal role for LPA and LPA1 in the regulation of urethral tonus and prostate cell proliferation. The potent urethral relaxation and inhibition of prostatic stromal cell growth indicate the potential of ASP6432 as a novel therapeutic agent for LUTS/BPH.

Introduction

Benign prostatic hyperplasia (BPH) is one of the most common chronic urological diseases among elderly men. The proliferation of periurethral prostate stromal cells and contraction of prostate and urethral smooth muscles contribute to the development of bladder outlet obstruction (BOO) and lower urinary tract symptoms (LUTS) (Roehrborn, 2008). α1-Adrenoceptor antagonists (α1-blockers) are prescribed as the first-line pharmacotherapy for LUTS associated with BPH (LUTS/BPH). α1-Blockers improve BOO by suppressing prostate and urethral smooth muscle contractions induced by norepinephrine released from sympathetic nerves. However, improvement of clinical symptoms with α1-blockers is moderate (40%–60%) compared with surgical intervention (60%–80%) (Speakman, 2001). In addition, α1-blockers are suggested to have little effect on prostate hyperplasia itself (Roehrborn, 2006). Steroid 5α-reductase inhibitors, another class of pharmacotherapies, reduce the size of the enlarged prostate and improve symptoms caused by mechanical obstruction. However, 5α-reductase inhibitors have a slower onset of efficacy and are slightly less effective at improving LUTS than α1-blockers (Djavan, 2003). In addition, 5α-reductase inhibitors have little effect on stromal cell hyperplasia (Marks et al., 1997), a key component of human BPH (Bartsch et al., 1979). Therefore, an agent that induces more potent urethral relaxation and suppression of stromal hyperplasia would improve treatment of LUTS/BPH patients.

Lysophosphatidic acid (LPA) is a simple glycerophospholipid produced in various parts of the body. In the lower urinary tract, LPA and autotaxin, an LPA-synthesizing enzyme, are present in the seminal plasma (Tanaka et al., 2004). In the hyperplastic prostate nodule, acylglycerol kinase, another LPA-synthesizing enzyme, is overexpressed (Zeng et al., 2009). LPA has diverse biologic effects, including smooth muscle contraction (Tokumura et al., 1980), as shown by its

ABSTRACT

Current pharmacotherapies for lower urinary tract symptoms associated with benign prostate hyperplasia (LUTS/BPH) are in need of improvement. Lysophosphatidic acid (LPA) is a phospholipid with various biologic functions. However, its exact role in the lower urinary tract and its target receptor subtype have not been fully elucidated. We investigated the role of LPA and the type 1 LPA receptor (LPA1) in urethral/prostatic contractile function and prostate cell proliferation by pharmacologically characterizing ASP6432 (potassium 1-((3,5-dimethoxy-4-methyl-N-(3-phenylpropyl)benzamido)methyl)-1,3-thiazole-4-carbonyl)-3-ethyl-2,2-dioxo-2H-diazathian-1-ide), a novel LPA1 antagonist. ASP6432 exhibited potent and selective antagonistic activity against LPA1 in cells expressing LPA receptor subtypes. In isolated rat tissue strips and anesthetized rats, ASP6432 concentration–dose-dependently inhibited LPA-induced urethra and prostate contractions. In addition, in anesthetized rats, ASP6432 maximally decreased the urethral perfusion pressure (UPP) in the absence of exogenous LPA stimulation by 43% from baseline, whereas tamsulosin, an α1-adrenoceptor antagonist, reduced UPP by 22%. Further, in human prostate stromal cells, ASP6432 significantly and concentration-dependently suppressed LPA-induced bromodeoxyuridine incorporation. These results demonstrate a pivotal role for LPA and LPA1 in the regulation of urethral tonus and prostate cell proliferation. The potent urethral relaxation and inhibition of prostatic stromal cell growth indicate the potential of ASP6432 as a novel therapeutic agent for LUTS/BPH.

Introduction

Benign prostatic hyperplasia (BPH) is one of the most common chronic urological diseases among elderly men. The proliferation of periurethral prostate stromal cells and contraction of prostate and urethral smooth muscles contribute to the development of bladder outlet obstruction (BOO) and lower urinary tract symptoms (LUTS) (Roehrborn, 2008). α1-Adrenoceptor antagonists (α1-blockers) are prescribed as the first-line pharmacotherapy for LUTS associated with BPH (LUTS/BPH). α1-Blockers improve BOO by suppressing prostate and urethral smooth muscle contractions induced by norepinephrine released from sympathetic nerves. However, improvement of clinical symptoms with α1-blockers is moderate (40%–60%) compared with surgical intervention (60%–80%) (Speakman, 2001). In addition, α1-blockers are suggested to have little effect on prostate hyperplasia itself (Roehrborn, 2006). Steroid 5α-reductase inhibitors, another class of pharmacotherapies, reduce the size of the enlarged prostate and improve symptoms caused by mechanical obstruction. However, 5α-reductase inhibitors have a slower onset of efficacy and are slightly less effective at improving LUTS than α1-blockers (Djavan, 2003). In addition, 5α-reductase inhibitors have little effect on stromal cell hyperplasia (Marks et al., 1997), a key component of human BPH (Bartsch et al., 1979). Therefore, an agent that induces more potent urethral relaxation and suppression of stromal hyperplasia would improve treatment of LUTS/BPH patients.

Lysophosphatidic acid (LPA) is a simple glycerophospholipid produced in various parts of the body. In the lower urinary tract, LPA and autotaxin, an LPA-synthesizing enzyme, are present in the seminal plasma (Tanaka et al., 2004). In the hyperplastic prostate nodule, acylglycerol kinase, another LPA-synthesizing enzyme, is overexpressed (Zeng et al., 2009). LPA has diverse biologic effects, including smooth muscle contraction (Tokumura et al., 1980), as shown by its
induction of urethral smooth muscle contraction (Saga et al., 2014), and cell proliferation (Daaka, 2002), such as of prostatic smooth muscle cells isolated from BPH patients (Adolfsson et al., 2002). These functions suggest that LPA may play a physiologic and pathophysiological role in the mechanical and functional BOO observed in BPH.

The functional roles of LPA are mediated by at least six G protein-coupled receptors, LPA receptors 1–6 (LPA1–6). Although these LPA receptors are broadly expressed, they vary significantly in their tissue distribution, and appear to have both distinct and overlapping biologic roles (Choi et al., 2010). LPA receptors modulate various intracellular signaling pathways by activating multiple heterotrimeric G proteins. The type 1 LPA receptor (LPA1) was the first identified LPA receptor subtype. LPA1 couples with Gi/o, Gq/11, and G12/13 to initiate downstream signaling cascades through phospholipase C, mitogen-activated protein kinase, Akt, and RhoA. LPA1 activation induces a range of cellular responses, including cell proliferation; cell migration and cytoskeletal changes; Ca2+ mobilization; and adenyl cyclase inhibition (Yung et al., 2014). An investigation using surgically obtained human prostate tissue samples demonstrated LPA1 expression in both the stroma and epithelia, and increased expression in the stroma of hyperplastic glands compared with that in surrounding benign glands (Zeng et al., 2009). LPA1 mediates LPA-induced induction of CYR61 (Wu et al., 2014), a molecule overexpressed in BPH and possibly linked to its pathogenesis (Saga et al., 2014), with some modifications. In brief, cells were seeded at a density of 15,000 (LPA1 and LPA2) or 20,000 (LPA3) cells per well in 96-well plates and incubated in culture medium containing 1% FBS and incubated in culture medium containing 1% FBS for 1 day. Human embryonic kidney 293 cells expressing human LPA1 were seeded at a density of 15,000 cells per well in 384-well plates and incubated in culture medium for 1 day.

On the day the measurements were to be taken, the cells were loaded with Fluo-4 acetoxyethyl ester dissolved in assay buffer (Hanks’ balanced salt solution containing 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (pH 7.4), 0.05% bovine serum albumin, and 2.5 mM probenecid) for 30 minutes at room temperature (LPA1, LPA2, and LPA3) or 30 minutes at 37°C (LPA4). The cells were incubated with test compounds for 2 (LPA1) or 4 minutes (LPA2 and LPA3) after washing or 30 minutes (LPA4) without washing, and LPA at a final concentration of 100 (LPA1), 30 (LPA2), or 800 nM (LPA3) was added. The final concentration of LPA was determined using the homogeneous time-resolved fluorescence assay using a cAMP femto 2 bulk kit (Cisbio, Codolet, France).

Measurement of Intracellular Ca2+ Concentration. The antagonistic effect of ASP6432 on human and rat LPA1 and its selectivity for human LPA1 over human LPA2 to human LPA4 were evaluated using Ca2+ flux assays previously used to investigate another LPA1 antagonist (Swaney et al., 2010), with some modifications. In brief, Chinese hamster ovary cells expressing human LPA5 were used.

Materials and Methods

Test Substances. LPA was purchased from Avanti Polar Lipids Inc. (Alabaster, AL), Enzo Life Sciences International Inc. (Plymouth Meeting, PA), and Cayman Chemical (Ann Arbor, MI). Based on published literature (Saga et al., 2014), 1-linolenoyl LPA was used for tissue contraction experiments, whereas 1-oleoyl LPA, the most commonly used form of LPA (Castilla-Ortega et al., 2014), was used for all other studies. ASP6432 and tamsulosin were synthesized at Astellas Pharma Inc. Concentrations were calculated using the molecular weight of the free form.

Cells/Recombinant Expression. Cells expressing LPA receptors were generated according to a previously reported method (Murai et al., 2017). Human and rat LPA1, human LPA2, and human LPA3 were stably expressed in Chinese hamster ovary cells and cultured in minimum essential medium-a containing 10% heat-inactivated fetal bovine serum (FBS), 1% penicillin/streptomycin, and 100 nM methotrexate. Human LPA2 was stably expressed in hepatoma tissue culture-4 (HTC4) cells and cultured in Dulbecco’s modified Eagle’s medium containing 10% heat-inactivated FBS, 1% penicillin/streptomycin, and 70 μM Zeocin (Invitrogen, Carlsbad, CA). Human LPA4 was stably expressed in human embryonic kidney cells and cultured in Dulbecco’s modified Eagle’s medium containing 10% FBS and 0.4 mg/ml G418.

Measurement of Intracellular cAMP. The effect of ASP6432 on LPA-induced cAMP production in cells expressing human LPA1 over human LPA2 to human LPA4 was evaluated using Ca2+ flux assays previously used to investigate another LPA1 antagonist (Swaney et al., 2010), with some modifications. LPA1 antagonists modulate urethral pressure (Terakado et al., 2002). These functions suggest that LPA may play a physiologic and pathophysiological role in the mechanical and functional BOO observed in BPH.
In the study conducted by Sakamoto et al., an intraperitoneal administration of urethane (1.2 g/kg) was used in female Wistar rats (Charles River Laboratories Japan Inc.) to induce anesthesia. The animals were subsequently anesthetized with an intraperitoneal injection of urethane (1.2 g/kg) before the addition of LPA (100 μM). The LPA-induced contractile response following treatment with ASP6432 was recorded and expressed as a percentage of the initial LPA response (prevalue). After washing, the strip was incubated with ASP6432 (0.01–10 μM) for 30 minutes before the addition of LPA (100 μM). The LPA-induced contractile response following treatment with ASP6432 or vehicle was recorded and expressed as a percentage of the initial LPA response (prevalue). For urethral strips, multiple concentrations (0.01–10 μM) of ASP6432 were tested in an incremental manner on the same strip. In contrast, only one concentration of ASP6432 was selected on each prostate strip for measurement. The tissue strips were repeatedly contracted with 60 mM KCl until the response became cloudy, making it difficult to continue with the experiment (data not shown). Therefore, we selected 100 μM LPA as the test concentration.

Measurement of Intraurethral Pressure in Rats. Male Wistar rats (Charles River Laboratories Japan Inc.) were anesthetized with an intraperitoneal administration of urethane (1.2 g/kg). A midline incision was made in the abdominal wall, and a 3.5 F sensor-tip transducer catheter (SPR-524; Millar Instruments, Inc., Houston, TX) was inserted into the urethra through a small incision at the bladder apex, and the tip was ligated to the bladder neck. Female rats were used because it was easier and less invasive to fix the position of the tip of the catheter at the bladder neck compared with that in male rats, as there is no need to remove the ventral lobe of the prostate. Physiologic saline was perfused into the urethra through the outer lumen of the catheter using an infusion pump (TE-331; Terumo, Tokyo, Japan) at 4.5 ml/h. UPP was recorded through the inner lumen of the catheter, which was connected to a pressure transducer with an amplifier (AP-621G; Nihon Kohden) and recorder (SR6221, SR6221, or SR6335; Grahtec Corporation, Kanagawa, Japan).

Each tissue strip was repeatedly contracted with 60 mM KCl until a stable response was obtained. Subsequently, 100 μM LPA was applied, and the maximum contractile response was recorded as the initial LPA response. The concentration of LPA was selected according to a previous study (Saga et al., 2014) and our preliminary study in which we aimed to generate the maximum contraction under experimentally feasible conditions. In our preliminary study, LPA-induced contraction was observed from 1 μM but did not reach maximum even at 100 μM (Supplemental Fig. 1). However, at 300 μM, the solution became cloudy, making it difficult to continue with the experiment (data not shown). Therefore, we selected 100 μM LPA as the test concentration.

After washing, the strip was incubated with ASP6432 (0.01–10 μM for urethra, 0.001–10 μM for prostate) or vehicle (DMSO, 0.1%) for 30 minutes before the addition of LPA (100 μM). The LPA-induced contractile response following treatment with ASP6432 or vehicle was recorded and expressed as a percentage of the initial LPA response (prevalue). For urethral strips, multiple concentrations (0.01–10 μM) of ASP6432 were tested in an incremental manner on the same strip because repeated treatment with DMSO and LPA did not affect the amplitude of the contractile response (data not shown). In contrast, only one concentration of ASP6432 was tested on each prostate strip due to the attenuation of LPA-induced contractile responses after multiple treatments (data not shown).

Measurement of Intraperitoneal Pressure in Rats. Male Wistar rats (Charles River Laboratories Japan Inc.) were anesthetized with an intraperitoneal administration of urethane (1.2 g/kg). A midline incision was made in the abdominal wall, and a 3.5 F sensor-tip transducer catheter (SPR-524; Millar Instruments, Inc., Houston, TX) was inserted into the urethra through a small incision at the superior aspect of the bladder. Intraperitoneal pressure (IPP) was measured using a pressure amplifier (AP-6016; Nihon Kohden) and analyzed using a digital acquisition and analysis system (PowerLab 8/30; AD Instruments, Colorado Springs, CO). For i.v. administration, a polyethylene catheter (PE-50) filled with physiologic saline containing sodium heparin was inserted into the jugular vein. Following a stabilization period of at least 30 minutes, vehicle (physiologic saline with 5% dimethylformamide) or ASP6432 (0.03, 0.1, 0.3, and 1 mg/kg) with incremental dosing at 15-minute intervals was intravenously administered. Half-maximal inhibitory concentration (IC50) values were calculated using sigmoid-Emax nonlinear regression analysis and expressed as the geometric mean with a 95% confidence interval for LPA1. In the tissue contraction study, Williams’ multiple comparisons test was used, and a probability value (P value) less than 0.025 indicated a statistically significant difference. In the in vivo studies, Dunnett’s multiple comparisons test and Student’s t test were used, and P < 0.05 was considered statistically significant. In the cell proliferation assay, paired t test and Williams’ multiple comparisons test were used, and P < 0.05 and P < 0.025 were considered statistically significant, respectively.

Results

Antagonistic Effect of ASP6432 on the LPA1 Receptor and Its Receptor Subtype Selectivity. The potency of ASP6432 for LPA1 and selectivity for the different LPA receptors were determined by Ca2+ flux assays (for LPA1 to LPA3) and a cAMP assay (for LPA3) using cells expressing human LPA1 to LPA3. ASP6432 concentration-dependently inhibited the LPA-stimulated increase in intracellular calcium ion concentration ([Ca2+]i) in cells expressing human LPA1 with an IC50 (95% confidence interval) of 11 (6.8–18) nM.
ASP6432 also inhibited the LPA-induced [Ca\textsuperscript{2+}] increase in cells expressing rat LPA\textsubscript{1} with an IC\textsubscript{50} of 30 (19–45) nM. ASP6432 inhibited the LPA-induced [Ca\textsuperscript{2+}] increase in cells expressing human LPA\textsubscript{1} with an IC\textsubscript{50} of 114 nM. In contrast, ASP6432 at concentrations up to 10,000 nM did not inhibit the LPA-induced increase in [Ca\textsuperscript{2+}] by 50% or more in cells expressing human LPA\textsubscript{2} or LPA\textsubscript{3}. Likewise, ASP6432 at concentrations up to 30,000 nM did not affect the LPA-induced increase in cAMP in cells expressing human LPA\textsubscript{5}. These results are summarized in Table 1.

We also evaluated the affinity of ASP6432 for a total of 57 receptors, ion channels, transporters, and enzymes. ASP6432 at 10,000 nM did not exhibit significant (>50%) effects on any of the targets examined, except for the human neurokinin 1 receptor with a K\textsubscript{i} value of 1400 nM (data not shown).

**Inhibition of LPA-Induced Contraction of Urethral and Prostate Strips Isolated from Rats by ASP6432.** Application of LPA (100 μM) induced contractions in urethral and prostate tissue strips. Pretreatment with ASP6432 (0.001 or 0.01–10 μM) inhibited these LPA-induced contractions in both tissues in a concentration-dependent manner (N = 5). This effect was statistically significant at ASP6432 concentrations of 0.1 μM and above, with almost complete inhibition observed at 10 μM (Fig. 2).

**Inhibition of LPA-Induced UPP Elevation in Anesthetized Rats by ASP6432.** Intravenous administration of LPA (3 mg/kg i.v.) increased the IUP (Fig. 3) by 759 mmH\textsubscript{2}O. This was comparable to the effects of phenylephrine shown in a previous study (approximately 12 cmH\textsubscript{2}O at 30 μg/kg i.v. in rats with no urethral ligation) (Akiyama et al., 1999). ASP6432 (0.03–1 mg/kg i.v.) dose-dependently inhibited the LPA-induced elevation of UPP (N = 6). This effect was statistically significant at ASP6432 doses of 0.3 mg/kg and above, with almost complete inhibition observed at 1 mg/kg (Fig. 3). The mean plasma concentrations of ASP6432 in rats at 6 and 30 minutes after single intravenous administration at 1 mg/kg were 477.28 and 77.65 ng/ml (851.24 and 138.49 nM, calculated from the free-form molecular weight of 560.69), respectively (Supplemental Table 1).

**Decrease in UPP by Tamsulosin and ASP6432 in Anesthetized Rats.** Intravenous administration of tamsulosin (0.003–0.03 mg/kg) decreased the UPP (N = 7–15). This effect was statistically significant at a dose of 0.01 mg/kg i.v., maximally decreasing the UPP by 21.6% from baseline (Fig. 4A). Intravenous administration of ASP6432 (0.1–3 mg/kg) decreased the UPP in a dose-dependent manner (N = 10). This effect was statistically significant at ASP6432 doses of 0.3 mg/kg i.v. and above. The decrease in UPP with ASP6432 reached a maximum of 42.5% at 3 mg/kg i.v. (Fig. 4B).

**Effect of ASP6432 on LPA-Induced Proliferation of Primary Cultured Human Prostate Stromal Cells.** LPA (10 μM) significantly enhanced the incorporation of BrdU into human prostate stromal cells (172.7% of the normal group). Treatment with ASP6432 (0.1–10 μM) suppressed LPA-induced BrdU incorporation in a concentration-dependent manner. This effect was statistically significant at ASP6432 concentrations of 0.3 μM and above, with almost complete suppression observed at 10 μM (Fig. 5).

**Discussion.**

We showed that ASP6432 had potent and selective antagonistic activity against LPA\textsubscript{1}, and suppressed not only LPA-induced urethral and prostatic contractions but also urethral pressure in the absence of external LPA stimulation. These results suggest that LPA\textsubscript{1} activation plays an important role in the physiologic regulation of urethral tonus. In addition, ASP6432 inhibited the LPA-induced proliferation of human prostate stromal cells. To our knowledge, this is the first study to demonstrate that an LPA\textsubscript{1} antagonist can modulate both LPA-induced urethral tonus and prostate stromal cell proliferation.

In our in vitro studies, ASP6432 exhibited a potent antagonistic effect against LPA\textsubscript{1}, and was more selective for LPA\textsubscript{1} by more than 10-fold over all other LPA receptor subtypes (Table 1) and other receptors, ion-channels, transporters, and enzymes tested. Although ASP6432 showed some antagonistic activity against LPA\textsubscript{4}, and its effect on LPA\textsubscript{6} was not investigated, ASP6432 appears to be one of the most potent LPA\textsubscript{1} antagonists among currently reported LPA receptor modulators (Llona-Minguez et al., 2015).

LPA was previously reported to induce contractions in rat urethral tissue strips at a magnitude comparable to that of phenylephrine, an α\textsubscript{1}-adrenoceptor agonist (Saga et al., 2014). However, the receptor subtype responsible for this effect was not identified. We showed that ASP6432 concentration-/dose-dependently inhibited LPA-induced contractions in rat urethral and prostate strips (Fig. 2) and UPP elevation in anesthetized rats (Fig. 3) with near-complete inhibition at the highest concentration/dose tested. Our results indicate that LPA\textsubscript{1} regulates LPA-induced urethra and prostatic contractions.

One notable finding in this study was that ASP6432 not only inhibited LPA-induced contractions, but also reduced the UPP in the absence of exogenous LPA stimulation in anesthetized rats (Fig. 4B). ASP6432 maximally decreased the UPP by 42.5% from baseline, which is more pronounced than that induced by tamsulosin in this study (maximum 21.6% decrease, Fig. 4A) at doses sufficient to inhibit phenylephrine-induced urethral pressure elevation (Ohtake et al., 2006). Female rats were used in our study because of the similar efficacy of tamsulosin when compared with male rats, the experimental benefit, and the potentially limited advantage of male rats as a model for urethral tonus in humans from an

|TABLE 1| Antagonistic activity of ASP6432 on LPA-induced cellular responses in cells expressing LPA\textsubscript{1} to LPA\textsubscript{5} receptors |
|---|---|---|---|---|---|---|---|
|LPA\textsubscript{1} (Human) | LPA\textsubscript{1} (Rat) | LPA\textsubscript{2} (Human) | LPA\textsubscript{3} (Human) | LPA\textsubscript{4} (Human) | LPA\textsubscript{5} (Human) |
|IC\textsubscript{50} (nM) | 11 | 30 | >10,000 | >10,000 | 114 | >30,000 |

LPA\textsubscript{1} Receptor Antagonism and Urethral and Prostate Function 393
The anatomic point of view. The tamsulosin-induced suppression of the UPP was similar to that demonstrated in a previous study in male rats (around 20% decrease) (Saga et al., 2014). Tamsulosin decreased the urethral pressure in male and female dogs at a similar dose range (Sudoh et al., 1996; Ohtake et al., 2004) and in healthy women at a dose approved for men with BPH (0.4 mg) (Reitz et al., 2004). These findings support the notion that the sympathetic nervous system and α1-adrenoceptors contribute to regulating physiologic urethral tonus (Fry et al., 2010) in both males and females. Another reason for using female animals was the experimental benefit for evaluating the perfusion pressure. In female rats, access to the bladder neck and subsequent securing of the catheter tip at the intended position was much easier and less invasive than in male rats, which helped ensure stable pressure measurements. Further, the use of male rats might not significantly increase the clinical relevance of the UPP compared with that of female rats, because the rat prostate is anatomically different from the human prostate in that it does not completely surround the urethra and, therefore, may not cause the mechanical and/or functional urethral obstruction like the prostate of a BPH patient does. These points indicate that the experimental conditions of this study were appropriate for examining the effect of a drug that potentially modulates the urethral contraction in vivo compared with a drug acting on the sympathetic nervous system.

LPA induced contraction of urethral strips at 1 μM and above in a previous study (Saga et al., 2014) and in the present study (Supplemental Fig. 1). The fact that the rat plasma LPA concentration reported in the previous study was in the micromolar order (around 1 μM) (Saga et al., 2014) suggests that LPA induces urethral contraction at a concentration similar to the endogenous concentration. In addition, previous studies have demonstrated that an inhibitor of autotaxin and another LPA1 antagonist decrease the IUP in the absence of exogenous LPA stimulation in rats (Saga et al., 2014; Terakado et al., 2016) to an extent similar to that observed with ASP6432 in this study. Moreover, pharmacokinetics data of ASP6432 in rats (Supplemental Table 1) support our hypothesis that ASP6432 reduces UPP by suppressing LPA1. The plasma concentration of ASP6432 at the efficacious dose for urethral pressure (0.3 mg/kg i.v., Fig. 4B) is estimated to be around 40–250 nM, which is comparable to the IC50 value of ASP6432 on rat LPA1 (30 nM, Table 1). Taken together, our results suggest that endogenous LPA constantly activates LPA1 and plays a significant role in the regulation of urethral tonus, which is suppressed by ASP6432, at least in rats.

LPA induces proliferation of human prostate stromal cells, similar to that observed for cells isolated from BPH patients (Adolfsson et al., 2002). ASP6432 suppressed this proliferation (Fig. 5). Our results suggest that LPA, in addition to its role in inducing urethral and prostate contractions, also regulates stromal cell proliferation via LPA1 and contributes to the
development of the two major components, mechanical and functional obstruction, of BOO. Because there is currently no pharmacotherapy that is simultaneously efficacious for both of these components, our findings indicate that LPA1 antagonists may represent a novel therapy with dual mechanisms for improving BOO. A similar concept was proposed using inhibitors of Rac, a small monomeric GTPase (Wang et al., 2015). Given that LPA1 may also potentially activate Rac (Van Leeuwen et al., 2003), it would be interesting to determine the relationship between LPA1 and Rac in lower urinary tract functions.

Since autotaxin is one of the primary enzymes responsible for LPA production, autotaxin inhibitors may theoretically have efficacy similar to LPA1 antagonists, such as in reducing the IUP as shown in a previous study (Saga et al., 2014). Various autotaxin inhibitors have been studied, and some are in clinical development. Although inhibition of LPA production may efficiently suppress the LPA-LPA receptor signaling axis, the risk of toxicity may be high due to the suppression of functions mediated by other LPA receptor subtypes. Indeed, autotaxin knockout mice show a more severe phenotype (lethal around embryonic day 10.5 due to defects in blood vessel formation) than LPA receptor knockout mice (Tanaka et al., 2006). Therefore, specific targeting of LPA1 may be more suitable for the treatment of non-life-threatening diseases such as BPH, which requires a high safety profile.

Our results provide various insights for further investigations into the role of LPA and LPA1. The physiologic and pathophysiologic role of the LPA-LPA1 signaling axis in the modulation of urethral pressure has not been extensively investigated. Currently, no study has directly measured the tissue concentration of LPA in the urethra or prostate, even though the presence of LPA in seminal plasma (Tanaka et al., 2004) and LPA-producing enzymes in the prostate (Zeng et al., 2009) suggests that it may be produced locally in these organs. The mechanism underlying LPA1 activation–induced urethral and prostate smooth muscle contractions has not been fully clarified. In mouse aorta, LPA1-mediated thromboxane A2 release has been suggested as a potential mechanism underlying smooth muscle contraction (Dancs et al., 2017). However, studies showing that an autotaxin inhibitor (Saga et al., 2014) and LPA1 antagonist (Terakado et al., 2016) decrease the urethral pressure without affecting blood pressure suggest the presence of an alternative mechanism for regulating urethral smooth muscle contraction. Further studies are required to unravel the mechanistic details. In addition, the role of LPA1 on urethral pressure during urine voiding needs to be determined. Since the sympathetic and parasympathetic nervous system regulate the on–off of the bladder and the urethral outlet functions in an antagonistic fashion for proper urine storage and voiding (Fowler et al., 2008), it would be worthwhile to investigate how the activity of LPA1 is regulated at bladder filling and urine voiding. The effect of LPA1 on axis, the risk of toxicity may be high due to the suppression of functions mediated by other LPA receptor subtypes. Indeed, autotaxin knockout mice show a more severe phenotype (lethal around embryonic day 10.5 due to defects in blood vessel formation) than LPA receptor knockout mice (Tanaka et al., 2006). Therefore, specific targeting of LPA1 may be more suitable for the treatment of non-life-threatening diseases such as BPH, which requires a high safety profile.

Our results provide various insights for further investigations into the role of LPA and LPA1. The physiologic and pathophysiologic role of the LPA-LPA1 signaling axis in the modulation of urethral pressure has not been extensively investigated. Currently, no study has directly measured the tissue concentration of LPA in the urethra or prostate, even though the presence of LPA in seminal plasma (Tanaka et al., 2004) and LPA-producing enzymes in the prostate (Zeng et al., 2009) suggests that it may be produced locally in these organs. The mechanism underlying LPA1 activation–induced urethral and prostate smooth muscle contractions has not been fully clarified. In mouse aorta, LPA1-mediated thromboxane A2 release has been suggested as a potential mechanism underlying smooth muscle contraction (Dancs et al., 2017). However, studies showing that an autotaxin inhibitor (Saga et al., 2014) and LPA1 antagonist (Terakado et al., 2016) decrease the urethral pressure without affecting blood pressure suggest the presence of an alternative mechanism for regulating urethral smooth muscle contraction. Further studies are required to unravel the mechanistic details. In addition, the role of LPA1 on urethral pressure during urine voiding needs to be determined. Since the sympathetic and parasympathetic nervous system regulate the on–off of the bladder and the urethral outlet functions in an antagonistic fashion for proper urine storage and voiding (Fowler et al., 2008), it would be worthwhile to investigate how the activity of LPA1 is regulated at bladder filling and urine voiding. The effect of LPA1 on
bladder function represents another area of interest. While the effect on pathologic prostate proliferation should ideally be assessed using in vivo models, fully validated animal models for stromal proliferation are currently lacking. Future studies on these aspects will allow for a more extensive characterization of the therapeutic potential of LPA1 antagonists in the treatment of BPH and associated LUTS.

In conclusion, we demonstrated the roles of LPA and LPA1 in urethral and prostate contraction and prostate stromal cell proliferation using ASP6432, a selective LPA1 antagonist. ASP6432 induced potent urethral relaxation compared with tamsulosin and inhibited prostate stromal cell growth, indicating the potential of an LPA1 antagonist as a novel therapy for LUTS/BPH.

Acknowledgments

We are grateful to Dr. Takatoshi Soga for the generation and provision of cells expressing LPA receptors.

Authorship Contributions

Participated in research design: Sakamoto, Noguchi, Ueshima, Hosogai, Ishizu, Ohtake, Sato, Takeda, Masuda.

Conducted experiments: Sakamoto, Noguchi, Ueshima, Yamakuni, Ohtake, Sato, Ishizu, Hosogai.

Contributed new reagents or analytic tools: Kawaminami.

Performed data analysis: Sakamoto, Noguchi, Ueshima, Yamakuni, Ishizu, Kawaminami, Takeda, Masuda.

Wrote or contributed to the writing of the manuscript: Sakamoto, Noguchi, Ueshima, Yamakuni, Ohtake, Sato, Hosogai, Ishizu, Kawaminami, Takeda, Masuda.

References


Address correspondence to: Kazuyuki Sakamoto, Research Program Management Office, Drug Discovery Research, Astellas Pharma Inc., 21, Miyukiigaoka, Tsukuba, Ibaraki 305-8585, Japan. E-mail:kazuyuki.sakamoto@astellas.com

396 Sakamoto et al.